Advances and issues in mantle cell lymphoma research: report of the 2014 Mantle Cell Lymphoma Consortium Workshop

References

• Lwin T, Zhao X, Cheng F, et al. A microenvironment-mediated c-Myc/miR-548m/HDAC6 amplification loop in non-Hodgkin B cell lymphomas. J Clin Invest 2013;123:4612–4626.
   PubMed Web of Science ®Google Scholar
• Shiloh Y, Ziv Y. The ATM protein: the importance of being active. J Cell Biol 2012;198:273–275.
   PubMed Web of Science ®Google Scholar
• Beà S, Valdés-Mas R, Navarro A, et al. Landscape of somatic mutations and clonal evolution in mantle cell lymphoma. Proc Natl Acad Sci U S A 2013;110:18250–18255.
   PubMed Web of Science ®Google Scholar
• Barastye-Lovejoy D, Lau SK, Boutros PC, et al. The c-Myc oncogene directly induces the H19 noncoding RNA by allele-specific binding to potentiate tumorigenesis. Cancer Res 2006;66:5330.
   PubMed Web of Science ®Google Scholar
• Gupta R, Shah N, Wang KC, et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature 2010;464:1071–1076.
   PubMed Web of Science ®Google Scholar
• Michalik KM, You X, Manavski Y, et al. Long noncoding RNA MALAT1 regulates endothelial cell function and vessel growth. Circ Res 2014;114:1389–1397.
   PubMed Web of Science ®Google Scholar
• Oberley MJ, Rajguru SA, Zhang C, et al. Immunohistochemical evaluation of MYC expression in mantle cell lymphoma. Histopathology 2013;63:499–508.
   PubMed Web of Science ®Google Scholar
• Wlodarska I, Meeus P, Stul M, et al. Variant t(23;11)(p11;q13) associated with the IgK-CCND1 rearrangement is a recurrent translocation in leukemic small-cell B-non-Hodgkin lymphoma. Leukemia 2004;18:1705–1710.
   PubMed Web of Science ®Google Scholar
• Espinet B, Salaverria I, Beà S, et al. Incidence and prognostic impact of secondary cytogenetic aberrations in a series of 145 patients with mantle cell lymphoma. Genes Chromosomes Cancer 2010;49:439–451.
   PubMed Web of Science ®Google Scholar
• Gopal AK, Rajendran JG, Gooley TA, et al. High-dose [131I] tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults > or = 60 years old with relapsed or refractory B-cell lymphoma. J Clin Oncol 2007;25: 1396–1402.
   PubMed Web of Science ®Google Scholar
• Gopal AK, Gooley TA, Rajendran JG, et al. Myeloablative I-131-tositumomab with escalating doses of fludarabine and autologous hematopoietic transplantation for adults age ≥ 60 years with B cell lymphoma. Biol Blood Marrow Transplant 2014;20:770–775.
   PubMed Web of Science ®Google Scholar
• Press OW, Eary JF, Gooley T, et al. A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood 2000;96:2934–2942.
   PubMed Web of Science ®Google Scholar
• Kolstad A, Laurell A, Jerkeman M, et al. Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma. Blood 2014;123:2953–2959.
   PubMed Web of Science ®Google Scholar
• Hermine OR, Hoster E, Szymczk M, et al. Alternating courses of 3x CHOP and 3x DHAP plus rituximab followed by a high dose Ara-C-containing myeloablative regimen and autologous stem cell transplantation (ASCT) increases overall survival when compared to 6 courses of CHOP plus rituximab followed by myeloablative radiochemotherapy and ASCT in mantle cell lymphoma: final analysis of the MCL Younger trial of the European Mantle Cell Lymphoma Network (MCL NET). Hematol Oncol 2013;31(Suppl 1):Abstract 86.
   Google Scholar
• Geisler CH, Kolstad A, Laurell A, et al. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 2008;112:2687–2693.
   PubMed Web of Science ®Google Scholar
• van ‘t Veer MB, de Jong D, MacKenzie M, et al. High-dose Ara-C and beam with autograft rescue in R-CHOP responsive mantle cell lymphoma patients. Br J Haematol 2009;144:524–530.
   PubMed Web of Science ®Google Scholar
• Hoster E, Geisler CH, Doorduijn JK, et al. Role of high-dose cytarabine and total body irradiation conditioning before autologous stem cell transplantation in mantle cell lymphoma - a comparison of Nordic MCL2, HOVON 45, and European MCL Younger trials. Blood 2013;122:Abstract 3367.
   Google Scholar
• Zoellner AK, Fritsch S, Prevalsek D, et al. Sequential therapy combining clofarabine and HLA-haploidentical hematopoietic stem cell transplantation in the treatment of refractory and advanced lymphoma: feasibility, toxicity and early outcome. Blood 2013;122:Abstract 4544.
   Google Scholar
• Ferrero S, Pastore A, Forstpointer R, et al. Radioimmunotherapy in relapsed/refractory mantle cell lymphoma patients: final results of a European MCL Network phase II trial. Blood 2013;122:Abstract 4384.
   PubMed Web of Science ®Google Scholar
• Hess G, Keller U, Witzens-Harig M, et al. Temsirolimus added to Bendamustin and Rituximab (BERT): Phase I results of a Phase I/II–Trial in patients with relapsed follicular lymphoma (FL) and Mantle Cell Lymphoma (MCL). Hematol Oncol 2013;31(Suppl 1):Abstract 149.
   Google Scholar
• Leonard JP, LaCasce AS, Smith MR, et al. Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma. Blood 2012;119:4597–4607.
   PubMed Web of Science ®Google Scholar
• Chiron D, DiLiberto M, Martin P, et al. Cell-Cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma. Cancer Disc 2014;4:1022–1035.
   Web of Science ®Google Scholar
• Schachter J, Katz U, Mahrer A, et al. Efficacy and safety of intravenous immunoglobulin in patients with metastatic melanoma. Ann N Y Acad Sci 2007;1110:305–314.
   PubMed Web of Science ®Google Scholar
• Baskar S, Suschak JM, Samija I, et al. A human monoclonal antibody drug and target discovery platform for B-cell chronic lymphocytic leukemia based on allogeneic hematopoietic stem cell transplantation and phage display. Blood 2009;114:4494–4502.
   PubMed Web of Science ®Google Scholar
• Baskar S, Wiestner A, Wilson WH, et al. Targeting malignant B cells with an immunotoxin against ROR1. MAbs 2012;4:349–361.
   PubMed Web of Science ®Google Scholar
• Dave H, Anver MR, Butcher DO, et al. Restricted cell surface expression of receptor tyrosine kinase ROR1 in pediatric B-lineage acute lymphoblastic leukemia suggests targetability with therapeutic monoclonal antibodies. PLoS One 2012;7:e52655.
   PubMed Web of Science ®Google Scholar
• Hudecek M, Lupo-Stanghellini MT, Kosasih PL, et al. Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells. Clin Cancer Res 2013;19:3153–3164.
   PubMed Web of Science ®Google Scholar
• Yang J, Baskar S, Kwong KY, et al. Therapeutic potential and challenges of targeting receptor tyrosine kinase ROR1 with monoclonal antibodies in B-cell malignancies. PLoS One 2011;6:e21018.
   PubMed Web of Science ®Google Scholar
• Li X, Yang J, Rader C. Antibody conjugation via one and two C-terminal selenocysteines. Methods 2014;65:133–138.
   PubMed Web of Science ®Google Scholar
• Porter DL, Levine BL, Kalos M, et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011;365:725–733.
   PubMed Web of Science ®Google Scholar
• Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013;368:1509–1518.
   PubMed Web of Science ®Google Scholar
• Kochenderfer JN, Dudley ME, Feldman SA, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 2012;119:2709–2720.
   PubMed Web of Science ®Google Scholar
• Zhao X, Bodo J, Sun D, et al. Combination of ibrutinib with ABT-199, a BCL-2 pathway inhibitor: effective therapeutic strategy in a novel mantle cell lymphoma cell line model. Blood 2013;122:Abstract 645.
   Google Scholar
• Fisher RI, Bernstein SH, Kahl BS, et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2006;24:4867–4874.
   PubMed Web of Science ®Google Scholar
• Goy A, Sinha R, Williams ME, et al. Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study. J Clin Oncol 2013;31:3688–3695.
   PubMed Web of Science ®Google Scholar
• Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 2013;369:507–516.
   PubMed Web of Science ®Google Scholar
• Hess G, Herbrecht R, Romaguera J, et al. Phase III study to evaluate temsirolimus compared with investigator’s choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 2009;27:3822–3829.
   PubMed Web of Science ®Google Scholar
• Kahl BS, Spurgeon SE, Furman RR, et al. A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL). Blood 2014;123:3398–3405.
   PubMed Web of Science ®Google Scholar
• Wang M, Fayad L, Wagner-Bartak N, et al. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. Lancet Oncol 2012;13:716–723.
   PubMed Web of Science ®Google Scholar
• Fenske TS, Zhang MJ, Carreras J, et al. Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: analysis of transplantation timing and modality. J Clin Oncol 2014;32:273–281.
   PubMed Web of Science ®Google Scholar
• Dietrich S, Boumendil A, Finel H, et al. Outcome and prognostic factors in patients with mantle-cell lymphoma relapsing after autologous stem-cell transplantation: a retrospective study of the European Group for Blood and Marrow Transplantation (EBMT). Ann Oncol 2014;25:1053–1058.
   PubMed Web of Science ®Google Scholar
• Gooley TA, Chien JW, Pergam SA, et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med 2010;363:2091–2101.
   PubMed Web of Science ®Google Scholar
• Robinson SP, Goldstone AH, Mackinnon S, et al. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood 2002;100: 4310–4316.
   PubMed Web of Science ®Google Scholar
• Venter JC, Adams MD, Myers EW, et al. The sequence of the human genome. Science 2001;291:1304–1351.
   PubMed Web of Science ®Google Scholar
• Lander ES, Linton LM, Birren B, et al. Initial sequencing and analysis of the human genome. Nature 2001;409:860–921.
   PubMed Web of Science ®Google Scholar
• Kridel R, Meissner B, Rogic S, et al. Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma. Blood 2012;119:1963–1971.
   PubMed Web of Science ®Google Scholar
• Meissner B, Kridel R, Lim RS, et al. The E3 ubiquitin ligase UBR5 is recurrently mutated in mantle cell lymphoma. Blood 2013;121: 3161–3164.
   PubMed Web of Science ®Google Scholar
• Rahal R, Frick M, Romero R, et al. Pharmacological and genomic profiling identifies NF-κB-targeted treatment strategies for mantle cell lymphoma. Nat Med 2014;20:87–92.
   PubMed Web of Science ®Google Scholar
• Zhang J, Jima D, Moffitt AB, et al. The genomic landscape of mantle cell lymphoma is related to the epigenetically determined chromatin state of normal B cells. Blood 2014;123:2988–2996.
   PubMed Web of Science ®Google Scholar